Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H26N4O2.CH4O3S |
| Molecular Weight | 462.562 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC1=C(C)N2C=C(C=C(NCC3=C(C)C=CC=C3C)C2=N1)C(=O)NCCO
InChI
InChIKey=QCHUWMQLRFKFDK-UHFFFAOYSA-N
InChI=1S/C21H26N4O2.CH4O3S/c1-13-6-5-7-14(2)18(13)11-23-19-10-17(21(27)22-8-9-26)12-25-16(4)15(3)24-20(19)25;1-5(2,3)4/h5-7,10,12,23,26H,8-9,11H2,1-4H3,(H,22,27);1H3,(H,2,3,4)
| Molecular Formula | CH4O3S |
| Molecular Weight | 96.106 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C21H26N4O2 |
| Molecular Weight | 366.4567 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Linaprazan is a member of a new group of acid-suppressing agents, which unlike proton pump inhibitors, act through potassium-competitive inhibition of the H+,K+-ATPase located in the apical membrane of parietal cells. It displayed rapid inhibition of acid production and had a prolonged, dose-dependent duration of effect. Linaprazan reduced porcine renal Na(+),K(+)-ATPase activity by 9+/-2%, demonstrating a high selectivity for H(+),K(+)-ATPase. It provided similar efficacy to esomeprazole in terms of esophagitis healing and heartburn control.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. | 2012 Jun |
|
| H+/K+-ATPase inhibitors: a patent review. | 2013 Jan |
|
| Evaluation of the use of Classical Nucleation Theory for predicting intestinal crystalline precipitation of two weakly basic BSC class II drugs. | 2014 Mar 12 |
|
| Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy. | 2014 May |
|
| Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression. | 2014 Sep |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:34:28 UTC 2023
by
admin
on
Fri Dec 15 15:34:28 UTC 2023
|
| Record UNII |
5P098C89CG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5P098C89CG
Created by
admin on Fri Dec 15 15:34:28 UTC 2023 , Edited by admin on Fri Dec 15 15:34:28 UTC 2023
|
PRIMARY | |||
|
11248232
Created by
admin on Fri Dec 15 15:34:28 UTC 2023 , Edited by admin on Fri Dec 15 15:34:28 UTC 2023
|
PRIMARY | |||
|
300000027093
Created by
admin on Fri Dec 15 15:34:28 UTC 2023 , Edited by admin on Fri Dec 15 15:34:28 UTC 2023
|
PRIMARY | |||
|
855998-67-3
Created by
admin on Fri Dec 15 15:34:28 UTC 2023 , Edited by admin on Fri Dec 15 15:34:28 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |